Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
about
Tenofovir-based pre-exposure prophylaxis for HIV preventionCombination prevention: new hope for stopping the epidemicEffectiveness of ART and condom use for prevention of sexual HIV transmission in serodiscordant couples: a systematic review and meta-analysisPreexposure prophylaxis for HIV prevention: where have we been and where are we going?HIV-1 prevention for HIV-1 serodiscordant couplesOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionThe potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling studyThe cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studiesAnalytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectivenessEffectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemicsHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactThe Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit AnalysisWhere to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?An action agenda for HIV and sex workers.HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities.Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk?Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.ARV-based HIV prevention for women - where we are in 2014.HIV treatment as prevention: optimising the impact of expanded HIV treatment programmesHIV treatment as prevention: issues in economic evaluation.Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as preventionEstimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.Individual-based simulation models of HIV transmission: reporting quality and recommendations.How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in ZambiaComparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South AfricaHIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventionsLay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study.Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study.Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and UgandaBeyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence.Risk Factor Associated with Negative Spouse HIV Seroconversion among Sero-Different Couples: A Nested Case-Control Retrospective Survey Study in 30 Counties in Rural China.Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention.
P2860
Q22242692-B52D9A77-98BA-4518-A478-BA5A26E878A6Q24630559-28191FEA-7124-49F7-A6E3-399B39CC21D0Q26824382-13BB265B-1F4A-43EB-AF5E-101EEB8896F0Q26825042-9D6EC2CC-9AE7-45DA-8675-624E9CC43054Q26996011-FEA75568-55B5-4170-BBDD-A5ECDC1AF092Q27023352-DD90C403-1144-4D6A-8E4C-D6543BD4AFA3Q28481276-8DFD69B7-C7F9-451A-A0E5-7238CC5075B7Q28484308-3BCC3CB3-9943-46EE-80FD-A3BBEAFBE5B8Q28487926-217B9BE9-ED60-46A5-8A1B-75523CB198A2Q28535414-3B9B57B2-C463-443B-A87D-5FEC936189F6Q28539234-9CF93618-F2D0-4BA3-BAC5-FE04A5A6E2ECQ28552455-5942DC4D-9498-4542-985C-8A618F950E70Q28608172-927694B7-9D52-4E5B-BE3F-E13DC4A47D15Q30352591-07EFCA39-BFFE-4825-90B7-E87EDAD425DAQ30365108-212A86AC-EDB9-44E3-8FE1-7B786B552F97Q30383181-2975BD76-5C58-4D1D-8F1C-00F3D02EE207Q33552342-964DAB3B-DA78-4612-8952-44B9B5A51437Q33634785-172B64F9-02D1-4AC6-9BAC-5520DAF7D692Q33670446-B8857C02-A5B9-431B-9023-69BE8F11149CQ33763000-2F789EAA-976F-42F8-8EE2-734BD0D9AB83Q34180729-AE380E2A-D436-4A17-8259-BF4FDF8895EBQ34339517-ADBCB423-2E58-4F25-BFEF-27A9DB9EFD2BQ34339555-02002812-7980-4095-8D39-6B085642E469Q34519553-BEDD2C16-6F44-4C32-B2D4-B1178B1C8200Q35007321-D1DE0CC5-0139-4B1D-A3AE-BB8A645A345AQ35010032-097E5055-2530-40C9-BE25-04407FDF7AA1Q35080217-7886BB16-9D95-454D-9DEE-48437328C80CQ35113480-EFA512B6-31E9-4829-ABDB-25D56D29A6FAQ35120904-3643CAF0-C2F0-437A-9814-006D123DEE0BQ35133519-39C196B7-2156-4F2D-ADA9-F5BC092C4D40Q35558214-94EF67D0-50D0-4173-AEFC-85913C21BCC8Q35575958-28B8C667-1987-48DC-A2E2-B75A059D7888Q35875746-5978C2F1-1557-42B6-9573-6D5FA265FD6CQ35875751-B3738090-35BA-4F87-B3DA-C9E53B83F8A5Q36003735-6B1A1A96-DE3A-4A05-B1FA-43B7ABD7EAADQ36057387-BDF2A2C7-F4C7-495B-9C91-4407AF311400Q36110276-69AF6453-6B79-4D1E-8751-B5AF129AA4FCQ36140719-B6CFA049-84A7-4C15-A86D-888D5D396CEDQ36163886-D0DC87DF-9D62-4E70-9E6F-82A7B71A24D0Q36165500-7E1CEBE2-CC94-4B2C-83A7-883CC10EF71A
P2860
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@ast
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@en
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@nl
type
label
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@ast
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@en
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@nl
prefLabel
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@ast
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@en
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@nl
P2093
P2860
P50
P921
P1433
P1476
Optimal uses of antiretroviral ...... uth Africa: a modelling study.
@en
P2093
Geoffrey P Garnett
Helen Rees
James McIntyre
Jared M Baeten
Leigh Johnson
Renee Heffron
Ruanne Barnabas
Sinead Delany
Timothy B Hallett
Íde Cremin
P2860
P304
P356
10.1371/JOURNAL.PMED.1001123
P407
P577
2011-11-15T00:00:00Z